Emerging molecular targets in melanoma invasion and metastasis

Pigment Cell and Melanoma Research

Volumn 26, Issue 1, 2013, Pages 39-57

  Orgaz, Jose L ^a   Sanz Moreno, Victoria ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anticancer therapy; Invasion; Melanoma; Metastasis; Molecular targets; Plasticity

Indexed keywords

BETA CATENIN; INTEGRIN; MEMBRANE RECEPTOR; MYOSIN ADENOSINE TRIPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR; WNT PROTEIN;

ANGIOGENESIS; CANCER INVASION; CLINICAL ASSESSMENT; CYTOSKELETON; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; MELANOMA CELL; MELANOMA METASTASIS; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84871438875     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12041     Document Type: Review

References (218)

1. Ackermann, J., Frutschi, M., Kaloulis, K., Mckee, T., Trumpp, A., and Beermann, F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005-4011.
2. Ahn, J., Sanz-Moreno, V., and Marshall, C.J. (2012). The metastasis gene NEDD9 product acts through integrin beta3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J. Cell Sci. 125, 1814-1826.
3. Al-Alousi, S., Carlson, J.A., Blessing, K., Cook, M., Karaoli, T., and Barnhill, R.L. (1996). Expression of basic fibroblast growth factor in desmoplastic melanoma. J. Cutan. Pathol. 23, 118-125.
4. Albino, A.P., Davis, B.M., and Nanus, D.M. (1991). Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51, 4815-4820.
5. Alonso, S.R., Ortiz, P., Pollan, M. et al. (2004). Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 164, 193-203.
6. Alonso, S.R., Tracey, L., Ortiz, P. et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67, 3450-3460.
7. Arozarena, I., Bischof, H., Gilby, D., Belloni, B., Dummer, R., and Wellbrock, C. (2011a). In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30, 4531-4543.
8. Arozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C., Hayward, R., Viros, A., Sahai, E., and Marais, R. (2011b). Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19, 45-57.
9. Ballestrem, C., Hinz, B., Imhof, B.A., and Wehrle-Haller, B. (2001). Marching at the front and dragging behind: differential alphaVbeta3-integrin turnover regulates focal adhesion behavior. J. Cell Biol. 155, 1319-1332.
10. Bar-Eli, M. (1997). Molecular mechanisms of melanoma metastasis. J. Cell. Physiol. 173, 275-278.
11. Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27-38.
12. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
13. Berton, S., Belletti, B., Wolf, K., Canzonieri, V., Lovat, F., Vecchione, A., Colombatti, A., Friedl, P., and Baldassarre, G. (2009). The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol. Cell. Biol. 29, 5031-5045.
14. Besson, A., Gurian-West, M., Schmidt, A., Hall, A., and Roberts, J.M. (2004). p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18, 862-876.
15. Bianchi, A.B., Hara, T., Ramesh, V. et al. (1994). Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat. Genet. 6, 185-192.
16. Bittner, M., Meltzer, P., Chen, Y. et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
17. Bosserhoff, A.K. (2006). Novel biomarkers in malignant melanoma. Clin. Chim. Acta 367, 28-35.
18. Boyle, G.M., Woods, S.L., Bonazzi, V.F., Stark, M.S., Hacker, E., Aoude, L.G., Dutton-Regester, K., Cook, A.L., Sturm, R.A., and Hayward, N.K. (2011). Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 24, 525-537.
19. Bustelo, X.R. (2012). Intratumoral stages of metastatic cells: a synthesis of ontogeny, Rho/Rac GTPases, epithelial-mesenchymal transitions, and more. BioEssays 34, 748-759.
20. Calvo, F., Sanz-Moreno, V., Agudo-Ibanez, L., Wallberg, F., Sahai, E., Marshall, C.J., and Crespo, P. (2011). RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation. Nat. Cell Biol. 13, 819-826.
21. Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
22. Carragher, N.O., Walker, S.M., Scott Carragher, L.A., Harris, F., Sawyer, T.K., Brunton, V.G., Ozanne, B.W., and Frame, M.C. (2006). Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 25, 5726-5740.
23. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
24. Carvajal, R.D., Antonescu, C.R., Wolchok, J.D. et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA 305, 2327-2334.
25. Charras, G.T., Hu, C.K., Coughlin, M., and Mitchison, T.J. (2006). Reassembly of contractile actin cortex in cell blebs. J. Cell Biol. 175, 477-490.
26. Chin, L. (2003). The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3, 559-570.
27. Chin, L., Tam, A., Pomerantz, J. et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472.
28. Chin, L., Garraway, L.A., and Fisher, D.E. (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182.
29. Clark, W.H. Jr. (1991). Human cutaneous malignant melanoma as a model for cancer. Cancer Metastasis Rev. 10, 83-88.
30. Clark, W.H. Jr, Elder, D.E., Guerry, D.T., Epstein, M.N., Greene, M.H., and Van Horn, M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 1147-1165.
31. Clark, E.A., Golub, T.R., Lander, E.S., and Hynes, R.O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535.
32. Damsky, W.E., Curley, D.P., Santhanakrishnan, M. et al. (2011). Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741-754.
33. Dancey, J.E. (2006). Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 5, 1065-1073.
34. Dang, D., Bamburg, J.R., and Ramos, D.M. (2006). Alphavbeta3 integrin and cofilin modulate K1735 melanoma cell invasion. Exp. Cell Res. 312, 468-477.
35. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr, You, M.J., Depinho, R.A., Mcmahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
36. Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105.
37. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
38. De Wever, O., Nguyen, Q.D., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., and Mareel, M. (2004). Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18, 1016-1018.
39. Demou, Z.N., Awad, M., Mckee, T., Perentes, J.Y., Wang, X., Munn, L.L., Jain, R.K., and Boucher, Y. (2005). Lack of telopeptides in fibrillar collagen I promotes the invasion of a metastatic breast tumor cell line. Cancer Res. 65, 5674-5682.
40. Demunter, A., Libbrecht, L., Degreef, H., De Wolf-Peeters, C., and Van Den Oord, J.J. (2002). Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod. Pathol. 15, 454-461.
41. Doe, C., Bentley, R., Behm, D.J. et al. (2007). Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 320, 89-98.
42. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
43. Eisen, T., Ahmad, T., Flaherty, K.T. et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586.
44. Eisenmann, K.M., Harris, E.S., Kitchen, S.M., Holman, H.A., Higgs, H.N., and Alberts, A.S. (2007). Dia-interacting protein modulates formin-mediated actin assembly at the cell cortex. Curr. Biol. 17, 579-591.
45. Etienne-Manneville, S., and Hall, A. (2002). Rho GTPases in cell biology. Nature 420, 629-635.
46. Fecher, L.A., Cummings, S.D., Keefe, M.J., and Alani, R.M. (2007). Toward a molecular classification of melanoma. J. Clin. Oncol. 25, 1606-1620.
47. Ferguson, J., Arozarena, I., Ehrhardt, M., and Wellbrock, C. (2012). Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene doi: 10.1038/onc.2012.25
48. Fernandez-Valle, C., Tang, Y., Ricard, J., Rodenas-Ruano, A., Taylor, A., Hackler, E., Biggerstaff, J., and Iacovelli, J. (2002). Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat. Genet. 31, 354-362.
49. Fine, B., Hodakoski, C., Koujak, S. et al. (2009). Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325, 1261-1265.
50. Flaherty, K.T. (2006). Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 12, 2366s-2370s.
51. Flaherty, K.T., Hodi, F.S., and Fisher, D.E. (2012). From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361.
52. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
53. Friedl, P. (2004). Prespecification and plasticity: shifting mechanisms of cell migration. Curr. Opin. Cell Biol. 16, 14-23.
54. Friedl, P., and Gilmour, D. (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 10, 445-457.
55. Friedl, P., and Wolf, K. (2009). Plasticity of cell migration: a multiscale tuning model. J. Cell Biol. 188, 11-19.
56. Gadea, G., De Toledo, M., Anguille, C., and Roux, P. (2007). Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 178, 23-30.
57. Gadea, G., Sanz-Moreno, V., Self, A., Godi, A., and Marshall, C.J. (2008). DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr. Biol. 18, 1456-1465.
58. Gaemers, I.C., Vos, H.L., Volders, H.H., Van Der Valk, S.W., and Hilkens, J. (2001). A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J. Biol. Chem. 276, 6191-6199.
59. Gaggioli, C., and Sahai, E. (2007). Melanoma invasion - current knowledge and future directions. Pigment Cell Res. 20, 161-172.
60. Gaggioli, C., Robert, G., Bertolotto, C. et al. (2007). Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J. Invest. Dermatol. 127, 400-410.
61. Garnett, M.J., and Marais, R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
62. Garnett, M.J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969.
63. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
64. Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C.S., and Sahai, E. (2009). Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 11, 1287-1296.
65. Goodall, J., Wellbrock, C., Dexter, T.J., Roberts, K., Marais, R., and Goding, C.R. (2004). The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24, 2923-2931.
66. Gray-Schopfer, V.C., Da Rocha Dias, S., and Marais, R. (2005). The role of B-RAF in melanoma. Cancer Metastasis Rev. 24, 165-183.
67. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007a). Melanoma biology and new targeted therapy. Nature 445, 851-857.
68. Gray-Schopfer, V.C., Karasarides, M., Hayward, R., and Marais, R. (2007b). Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 67, 122-129.
69. Gutheil, J.C., Campbell, T.N., Pierce, P.R., Watkins, J.D., Huse, W.D., Bodkin, D.J., and Cheresh, D.A. (2000). Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. 6, 3056-3061.
70. Haass, N.K., Smalley, K.S., and Herlyn, M. (2004). The role of altered cell-cell communication in melanoma progression. J. Mol. Histol. 35, 309-318.
71. Han, J., Luby-Phelps, K., Das, B., Shu, X., Xia, Y., Mosteller, R.D., Krishna, U.M., Falck, J.R., White, M.A., and Broek, D. (1998). Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279, 558-560.
72. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
73. Hegerfeldt, Y., Tusch, M., Brocker, E.B., and Friedl, P. (2002). Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res. 62, 2125-2130.
74. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
75. Hendrix, M.J., Seftor, E.A., Hess, A.R., and Seftor, R.E. (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411-421.
76. Higashi, M., Shimokawa, H., Hattori, T., Hiroki, J., Mukai, Y., Morikawa, K., Ichiki, T., Takahashi, S., and Takeshita, A. (2003). Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93, 767-775.
77. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
78. Hoek, K.S. (2007). DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res. 20, 466-484.
79. Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290-302.
80. Hofmann, U.B., Westphal, J.R., Van Muijen, G.N., and Ruiter, D.J. (2000). Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115, 337-344.
81. Homsi, J., Cubitt, C.L., Zhang, S., Munster, P.N., Yu, H., Sullivan, D.M., Jove, R., Messina, J.L., and Daud, A.I. (2009). Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 19, 167-175.
82. Hoshino, D., Koshikawa, N., and Seiki, M. (2011). A p27(kip1)-binding protein, p27RF-Rho, promotes cancer metastasis via activation of RhoA and RhoC. J. Biol. Chem. 286, 3139-3148.
83. Hsu, M.Y., Shih, D.T., Meier, F.E., Van Belle, P., Hsu, J.Y., Elder, D.E., Buck, C.A., and Herlyn, M. (1998). Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am. J. Pathol. 153, 1435-1442.
84. Huntington, J.T., Shields, J.M., Der, C.J., Wyatt, C.A., Benbow, U., Slingluff, C.L. Jr, and Brinckerhoff, C.E. (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem. 279, 33168-33176.
85. Ilina, O., and Friedl, P. (2009). Mechanisms of collective cell migration at a glance. J. Cell Sci. 122, 3203-3208.
86. Ishizaki, T., Uehata, M., Tamechika, I., Keel, J., Nonomura, K., Maekawa, M., and Narumiya, S. (2000). Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57, 976-983.
87. Itoh, M., Murata, T., Suzuki, T., Shindoh, M., Nakajima, K., Imai, K., and Yoshida, K. (2006). Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195-1204.
88. Jacobelli, J., Bennett, F.C., Pandurangi, P., Tooley, A.J., and Krummel, M.F. (2009). Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration. J. Immunol. 182, 2041-2050.
89. Ji, Z., Flaherty, K.T., and Tsao, H. (2012). Targeting the RAS pathway in melanoma. Trends Mol. Med. 18, 27-35.
90. Jiang, K., Sun, J., Cheng, J., Djeu, J.Y., Wei, S., and Sebti, S. (2004). Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 24, 5565-5576.
91. Jiang, X., Zhou, J., Yuen, N.K., Corless, C.L., Heinrich, M.C., Fletcher, J.A., Demetri, G.D., Widlund, H.R., Fisher, D.E., and Hodi, F.S. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 7726-7732.
92. Kajita, M., Mcclinic, K.N., and Wade, P.A. (2004). Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol. Cell. Biol. 24, 7559-7566.
93. Kelleher, F.C., and McArthur, G.A. (2012). Targeting NRAS in melanoma. Cancer J. 18, 132-136.
94. Kim, M., Gans, J.D., Nogueira, C. et al. (2006). Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 1269-1281.
95. Kimura, Y., Koga, H., Araki, N. et al. (1998). The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat. Med. 4, 915-922.
96. Kitzing, T.M., Wang, Y., Pertz, O., Copeland, J.W., and Grosse, R. (2010). Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene 29, 2441-2448.
97. Kortylewski, M., Jove, R., and Yu, H. (2005). Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24, 315-327.
98. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
99. Kuphal, S., Bauer, R., and Bosserhoff, A.K. (2005a). Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 24, 195-222.
100. Kuphal, S., Palm, H.G., Poser, I., and Bosserhoff, A.K. (2005b). Snail-regulated genes in malignant melanoma. Melanoma Res. 15, 305-313.
101. Kuratomi, Y., Nomizu, M., Nielsen, P.K., Tanaka, K., Song, S.Y., Kleinman, H.K., and Yamada, Y. (1999). Identification of metastasis-promoting sequences in the mouse laminin alpha 1 chain. Exp. Cell Res. 249, 386-395.
102. Kwon, T., Kwon, D.Y., Chun, J., Kim, J.H., and Kang, S.S. (2000). Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J. Biol. Chem. 275, 423-428.
103. Ladhani, O., Sanchez-Martinez, C., Orgaz, J.L., Jimenez, B., and Volpert, O.V. (2011). Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia 13, 633-642.
104. Lallemand, D., Curto, M., Saotome, I., Giovannini, M., and Mcclatchey, A.I. (2003). NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17, 1090-1100.
105. Lammermann, T., and Sixt, M. (2009). Mechanical modes of 'amoeboid' cell migration. Curr. Opin. Cell Biol. 21, 636-644.
106. Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414.
107. Li, A., Ma, Y., Yu, X. et al. (2011). Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod- driven motility and cell-cycle progression. Dev. Cell 21, 722-734.
108. Liang, S., Sharma, A., Peng, H.H., Robertson, G., and Dong, C. (2007). Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 67, 5814-5820.
109. Liao, J.K., Seto, M., and Noma, K. (2007). Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 50, 17-24.
110. Lindsay, C.R., Lawn, S., Campbell, A.D. et al. (2011). P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat. Commun. 2, 555.
111. Liu, W., Monahan, K.B., Pfefferle, A.D. et al. (2012). LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21, 751-764.
112. Loge, C., Wallez, V., Scalbert, E., Cario-Tourmaniantz, C., Loirand, G., Pacaud, P., and Lesieur, D. (2002). Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885. J. Enzyme Inhib. Med. Chem. 17, 381-390.
113. Lomuto, M., Calabrese, P., and Giuliani, A. (2004). Prognostic signs in melanoma: state of the art. J. Eur. Acad. Dermatol. Venereol. 18, 291-300.
114. Lopez-Otin, C., and Matrisian, L.M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
115. Lorentzen, A., Bamber, J., Sadok, A., Elson-Schwab, I., and Marshall, C.J. (2011). An ezrin-rich, rigid uropod-like structure directs movement of amoeboid blebbing cells. J. Cell Sci. 124, 1256-1267.
116. MacDougall, J.R., Bani, M.R., Lin, Y., Rak, J., and Kerbel, R.S. (1995). The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res. 55, 4174-4181.
117. Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419.
118. Mahabeleshwar, G.H., and Byzova, T.V. (2007). Angiogenesis in melanoma. Semin. Oncol. 34, 555-565.
119. Makabe, T., Saiki, I., Murata, J., Ohdate, Y., Kawase, Y., Taguchi, Y., Shimojo, T., Kimizuka, F., Kato, I., and Azuma, I. (1990). Modulation of haptotactic migration of metastatic melanoma cells by the interaction between heparin and heparin-binding domain of fibronectin. J. Biol. Chem. 265, 14270-14276.
120. Manchanda, N., Lyubimova, A., Ho, H.Y., James, M.F., Gusella, J.F., Ramesh, N., Snapper, S.B., and Ramesh, V. (2005). The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function. J. Biol. Chem. 280, 12517-12522.
121. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752.
122. Marshall, J.F., Rutherford, D.C., Happerfield, L., Hanby, A., Mccartney, A.C., Newton-Bishop, J., and Hart, I.R. (1998). Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br. J. Cancer 77, 522-529.
123. Mayer, E.L., and Krop, I.E. (2010). Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer Res. 16, 3526-3532.
124. McGill, G.G., Haq, R., Nishimura, E.K., and Fisher, D.E. (2006). c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 281, 10365-10373.
125. Melchiori, A., Mortarini, R., Carlone, S., Marchisio, P.C., Anichini, A., Noonan, D.M., and Albini, A. (1995). The alpha 3 beta 1 integrin is involved in melanoma cell migration and invasion. Exp. Cell Res. 219, 233-242.
126. Miller, A.J., and Mihm, M.C. Jr. (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
127. Montagut, C., Sharma, S.V., Shioda, T. et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861.
128. Montero, J.C., Seoane, S., Ocana, A., and Pandiella, A. (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 17, 5546-5552.
129. Natali, P.G., Nicotra, M.R., Winkler, A.B., Cavaliere, R., Bigotti, A., and Ullrich, A. (1992). Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int. J. Cancer 52, 197-201.
130. Nimnual, A.S., Yatsula, B.A., and Bar-Sagi, D. (1998). Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279, 560-563.
131. Niu, G., Wright, K.L., Huang, M. et al. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008.
132. Obremski, V.J., Hall, A.M., and Fernandez-Valle, C. (1998). Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J. Neurobiol. 37, 487-501.
133. Omholt, K., Platz, A., Ringborg, U., and Hansson, J. (2001). Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int. J. Cancer 92, 839-842.
134. Orgaz, J.L., Ladhani, O., Hoek, K.S. et al. (2009). Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 28, 4147-4161.
135. Overall, C.M., and Kleifeld, O. (2006). Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239.
136. Overall, C.M., and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
137. Packer, L.M., East, P., Reis-Filho, J.S., and Marais, R. (2009). Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 22, 785-798.
138. Palamidessi, A., Frittoli, E., Garre, M., Faretta, M., Mione, M., Testa, I., Diaspro, A., Lanzetti, L., Scita, G., and Di Fiore, P.P. (2008). Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 134, 135-147.
139. Parri, M., Taddei, M.L., Bianchini, F., Calorini, L., and Chiarugi, P. (2009). EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 69, 2072-2081.
140. Patel, S.R., Jenkins, J., Papadopolous, N., Burgess, M.A., Plager, C., Gutterman, J., and Benjamin, R.S. (2001). Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 92, 1347-1348.
141. Pedranzini, L., Dechow, T., Berishaj, M., Comenzo, R., Zhou, P., Azare, J., Bornmann, W., and Bromberg, J. (2006). Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 66, 9714-9721.
142. Peterson, A.C., Swiger, S., Stadler, W.M., Medved, M., Karczmar, G., and Gajewski, T.F. (2004). Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res. 10, 4048-4054.
143. Petrie, R.J., Doyle, A.D., and Yamada, K.M. (2009). Random versus directionally persistent cell migration. Nat. Rev. Mol. Cell Biol. 10, 538-549.
144. Pinner, S., and Sahai, E. (2008). PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat. Cell Biol. 10, 127-137.
145. Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., and Sahai, E. (2009). Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 69, 7969-7977.
146. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20.
147. Posey, J.A., Khazaeli, M.B., Delgrosso, A., Saleh, M.N., Lin, C.Y., Huse, W., and Lobuglio, A.F. (2001). A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 16, 125-132.
148. Poulikakos, P.I., Xiao, G.H., Gallagher, R., Jablonski, S., Jhanwar, S.C., and Testa, J.R. (2006). Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25, 5960-5968.
149. Reifenberger, J., Knobbe, C.B., Wolter, M., Blaschke, B., Schulte, K.W., Pietsch, T., Ruzicka, T., and Reifenberger, G. (2002). Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 100, 549-556.
150. Ridley, A.J., Schwartz, M.A., Burridge, K., Firtel, R.A., Ginsberg, M.H., Borisy, G., Parsons, J.T., and Horwitz, A.R. (2003). Cell migration: integrating signals from front to back. Science 302, 1704-1709.
151. Rimm, D.L., Caca, K., Hu, G., Harrison, F.B., and Fearon, E.R. (1999). Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325-329.
152. Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte, B.M., Pappin, D., Das, P., Waterfield, M.D., Ridley, A., and Downward, J. (1997). Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-467.
153. Rofstad, E.K., and Halsor, E.F. (2000). Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60, 4932-4938.
154. Rosai, J., and Ackerman, L.V. (2004). Rosai and Ackerman′s Surgical Pathology (Edinburgh, New York: Mosby).
155. Rose-John, S., Waetzig, G.H., Scheller, J., Grotzinger, J., and Seegert, D. (2007). The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 11, 613-624.
156. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275, 1790-1792.
157. Sabeh, F., Shimizu-Hirota, R., and Weiss, S.J. (2009). Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 185, 11-19.
158. Sahai, E. (2005). Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev. 15, 87-96.
159. Sahai, E., and Marshall, C.J. (2002). RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133-142.
160. Sahai, E., and Marshall, C.J. (2003). Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 5, 711-719.
161. Sahai, E., Garcia-Medina, R., Pouyssegur, J., and Vial, E. (2007). Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. J. Cell Biol. 176, 35-42.
162. Sanz-Moreno, V., and Marshall, C.J. (2010). The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr. Opin. Cell Biol. 22, 690-696.
163. Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., and Marshall, C.J. (2008). Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510-523.
164. Sanz-Moreno, V., Gaggioli, C., Yeo, M. et al. (2011). ROCK and JAK1 signalling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20, 229-245.
165. Sasaki, Y., Suzuki, M., and Hidaka, H. (2002). The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93, 225-232.
166. Seftor, R.E., Seftor, E.A., and Hendrix, M.J. (1999). Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev. 18, 359-375.
167. Seftor, E.A., Brown, K.M., Chin, L. et al. (2005). Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res. 65, 10164-10169.
168. Sekulic, A., Haluska, P. Jr, Miller, A.J. et al. (2008). Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin. Proc. 83, 825-846.
169. Shaw, R.J., and Cantley, L.C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430.
170. Shaw, R.J., Paez, J.G., Curto, M. et al. (2001). The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1, 63-72.
171. Shimokawa, H., Seto, M., Katsumata, N. et al. (1999). Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43, 1029-1039.
172. Slominski, A., Tobin, D.J., Shibahara, S., and Wortsman, J. (2004). Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84, 1155-1228.
173. Smalley, K.S., Xiao, M., Villanueva, J. et al. (2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28, 85-94.
174. Soengas, M.S., and Lowe, S.W. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151.
175. Solit, D.B., Garraway, L.A., Pratilas, C.A. et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
176. Somlyo, A.P., and Somlyo, A.V. (2003). Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83, 1325-1358.
177. Song, L., Turkson, J., Karras, J.G., Jove, R., and Haura, E.B. (2003). Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150-4165.
178. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
179. Stoletov, K., Montel, V., Lester, R.D., Gonias, S.L., and Klemke, R. (2007). High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc. Natl Acad. Sci. USA 104, 17406-17411.
180. Su, F., Viros, A., Milagre, C. et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
181. Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., and Kawakami, Y. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039.
182. Summy, J.M., and Gallick, G.E. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22, 337-358.
183. Takeda, K., Yasumoto, K., Takada, R., Takada, S., Watanabe, K., Udono, T., Saito, H., Takahashi, K., and Shibahara, S. (2000). Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275, 14013-14016.
184. Tamariz, E., and Grinnell, F. (2002). Modulation of fibroblast morphology and adhesion during collagen matrix remodeling. Mol. Biol. Cell 13, 3915-3929.
185. Tarhini, A.A., and Agarwala, S.S. (2006). Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther. 19, 19-25.
186. Teddy, J.M., and Kulesa, P.M. (2004). In vivo evidence for short- and long-range cell communication in cranial neural crest cells. Development 131, 6141-6151.
187. Thomas, A.J., and Erickson, C.A. (2008). The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res. 21, 598-610.
188. Topczewska, J.M., Postovit, L.M., Margaryan, N.V., Sam, A., Hess, A.R., Wheaton, W.W., Nickoloff, B.J., Topczewski, J., and Hendrix, M.J. (2006). Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 12, 925-932.
189. Trikha, M., Zhou, Z., Nemeth, J.A., Chen, Q., Sharp, C., Emmell, E., Giles-Komar, J., and Nakada, M.T. (2004). CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110, 326-335.
190. Tsao, H., Chin, L., Garraway, L.A., and Fisher, D.E. (2012). Melanoma: from mutations to medicine. Genes Dev. 26, 1131-1155.
191. Ugurel, S., Houben, R., Schrama, D., Voigt, H., Zapatka, M., Schadendorf, D., Brocker, E.B., and Becker, J.C. (2007). Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin. Cancer Res. 13, 6344-6350.
192. Valastyan, S., and Weinberg, R.A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292.
193. Van Belle, P.A., Elenitsas, R., Satyamoorthy, K. et al. (1999). Progression-related expression of beta3 integrin in melanomas and nevi. Hum. Pathol. 30, 562-567.
194. Van Goethem, E., Poincloux, R., Gauffre, F., Maridonneau-Parini, I., and Le Cabec, V. (2010). Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J. Immunol. 184, 1049-1061.
195. Vega, F.M., and Ridley, A.J. (2008). Rho GTPases in cancer cell biology. FEBS Lett. 582, 2093-2101.
196. Vergani, E., Vallacchi, V., Frigerio, S. et al. (2011). Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13, 1132-1142.
197. Vigil, D., Kim, T.Y., Plachco, A. et al. (2012). ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 72, 5338-5347.
198. Villanueva, J., and Herlyn, M. (2009). Melanoma. In Encyclopedia of Life Sciences (ELS), (Chichester: John Wiley & Sons, Ltd), pp. 1-9.
199. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., and Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120.
200. Wan, P.T., Garnett, M.J., Roe, S.M. et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
201. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
202. Wellbrock, C., and Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170, 703-708.
203. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C.J., and Marais, R. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
204. Wilhelm, S.M., Carter, C., Tang, L. et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109.
205. Wilkinson, S., Paterson, H.F., and Marshall, C.J. (2005). Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 7, 255-261.
206. Willmore-Payne, C., Holden, J.A., Tripp, S., and Layfield, L.J. (2005). Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum. Pathol. 36, 486-493.
207. Wolf, K., Mazo, I., Leung, H., Engelke, K., Von Andrian, U.H., Deryugina, E.I., Strongin, A.Y., Brocker, E.B., and Friedl, P. (2003). Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160, 267-277.
208. Woods, D., Cherwinski, H., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P.F., Saylor, V.L., and Mcmahon, M. (2001). Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 21, 3192-3205.
209. Wu, M., Hemesath, T.J., Takemoto, C.M., Horstmann, M.A., Wells, A.G., Price, E.R., Fisher, D.Z., and Fisher, D.E. (2000). c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14, 301-312.
210. Wu, H., Goel, V., and Haluska, F.G. (2003). PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122.
211. Xie, T.X., Wei, D., Liu, M., Gao, A.C., Ali-Osman, F., Sawaya, R., and Huang, S. (2004). Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550-3560.
212. Xu, H.M., and Gutmann, D.H. (1998). Merlin differentially associates with the microtubule and actin cytoskeleton. J. Neurosci. Res. 51, 403-415.
213. Yamazaki, D., Kurisu, S., and Takenawa, T. (2009). Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 28, 1570-1583.
214. Yeatman, T.J. (2004). A renaissance for SRC. Nat. Rev. Cancer 4, 470-480.
215. Yu, H., and Jove, R. (2004). The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105.
216. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809.
217. Yue, P., and Turkson, J. (2009). Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs 18, 45-56.
218. Zhang, S., and Yu, D. (2012). Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol. Sci. 33, 122-128.